Jump to content
Main menu
Main menu
move to sidebar
hide
Navigation
Main page
Recent changes
Random page
Help about MediaWiki
Special pages
Surgopaedia
Search
Search
Appearance
Create account
Log in
Personal tools
Create account
Log in
Pages for logged out editors
learn more
Contributions
Talk
Editing
Soft tissue sarcoma
(section)
Page
Discussion
English
Read
Edit
Edit source
View history
Tools
Tools
move to sidebar
hide
Actions
Read
Edit
Edit source
View history
General
What links here
Related changes
Page information
Appearance
move to sidebar
hide
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
=== '''Desmoid fibromatosis''' (aka desmoid tumour, fibromatosis, aggressive fibromatosis) === ** Non-metastatic neoplasm but aggressive locally ** Can be a/w FAP/Gardner syndrome/Turcot syndrome, concurrent with a pregnancy (often stabilises post-partum), or sporadically ** Pathophysiology *** Clonal proliferations of myofibroblasts - well-differentiated bundles of spindle cells with abundant collagenous matrix *** Often indolent tumours which show no growth after presentation *** Sporadic (75-85%): **** Associated with mutations of CTNNB1 gene -> beta-catenin accumulation and nuclear effects including proliferation **** Can occur after surgery, trauma, pregnancy, OCP use **** Those occurring in pregnancy have a good prognosis, and can usually be monitored throughout pregnancy *** Associated with FAP: **** 10-15% of patients with FAP will develop a desmoid tumour, mostly within mesentery or abdominal wall, at the site of the scar **** Caused by germline APC mutations -> beta-catenin accumulation and nuclear effects including proliferation **** Aggressive, often involving mesentery, occasionally encasing mesenteric vessels ** Workup *** MRI or CT - homogenous and solid - indistinguishable from other STS subtypes *** Diagnosis established by core biopsy, if tumour histology will alter treatment ** Management *** Primary non-operative management, especially for tumours in difficult locations, due to the high risk of local recurrence and possibility of regression (20-30%) *** Systemic therapies should probably be trialled prior to surgery **** Nirogacestat - oral gamma secretase inhibitor **** Tyrosine kinase inhibitors - sorafenib **** Cytotoxic chemotherapy can be used for locally aggressive or symptomatic tumours **** It's unclear whether NSAIDs and hormonal therapies are effective *** Radiotherapy can be used for extremity tumours, or other locations without other good treatment options *** '''Asymptomatic or mildly symptomatic:''' **** Initial active surveillance (imaging every 3-6 months) *** '''Moderately or severely symptomatic:''' **** ''Depends on FAP status, location, toxicity of therapy, and desired urgency of response'' **** FAP - usually trial systemic first **** Sporadic ***** Abdo wall - resection and reconstruction ***** Other location - prefer systemic therapy first *** '''Imminent threat to life (e.g. bowel obstruction):''' **** Surgery, if resectable *** '''Recurrent/relapsed disease:''' **** Surgical resection +/- adjuvant radiotherapy as salvage ** Prognosis *** 30% spontaneously regress *** Sporadic abdo wall desmoids do have a good surgical outcome though
Summary:
Please note that all contributions to Surgopaedia may be edited, altered, or removed by other contributors. If you do not want your writing to be edited mercilessly, then do not submit it here.
You are also promising us that you wrote this yourself, or copied it from a public domain or similar free resource (see
Surgopaedia:Copyrights
for details).
Do not submit copyrighted work without permission!
Cancel
Editing help
(opens in new window)
Search
Search
Editing
Soft tissue sarcoma
(section)
Add topic